A rare breast tumor: solid neuroendocrine carcinoma.

Background: Solid neuroendocrine carcinoma of breast (NECB) is extremely rare. In this paper, we present a case of inflammatory primary solid neuroendocrine carcinoma of breast managed by surgery and chemotherapy and a brief review of the epidemiology, clinical features, diagnosis, pathologic features, treatment, and prognosis of solid NECB.
Methods: A 63-year-old woman was admitted in our institution with inflammatory primary solid neuroendocrine carcinoma of breast. A bulky mass of 6,5 cm tumor was located in the upper-outer and intern quadrant of her right breast. The patient underwent neo-adjuvant chemotherapy, and subsequent radical mastectomy with axillary lymph node dissection. Microscopically, the tumor was classified as solid cohesive, the tumor cells were positive for neuroendocrine markers chromogranin A and synaptophysin. 19 lymph nodes of 27 were metastatic.
Results: Local recurrence and metastatic progression was noted only one month after the surgery, the patient was managed by chemotherapy and hormone-therapy. She is still alive, 24 months after diagnosis.
Conclusions: Solid neuroendocrine carcinoma is a subtype of mammary carcinoma with several distinctive features. Because of the rarity of this disease, there is no standard treatment, they are characterized by a higher propensity for local and distant recurrence, This case reinforces the importance to explore the novels therapeutics regimen and one of ways to explore is the use of VP16-cisplatine as treatment as it was partially efficacy for this kind of tumor.